Agency for the Development of the Pharmaceutical Industry

What Agency for the Development of the Pharmaceutical Industry does

The Agency for the Development of the Pharmaceutical Industry (Tibbiyot va farmatsevtika tarmog'ini rivojlantirish agentligi) is a government regulatory entity of Uzbekistan, operating under the Ministry of Health, that holds exclusive statutory authority over pharmaceutical sector registration, licensing, GMP certification, and reference pricing. Founded in 2017 and headquartered in Tashkent, the agency regulates an ecosystem of 443 pharmaceutical manufacturers, 464 distributors, and 13,725 pharmacies, overseeing a database of 44,413 drug products, 11,458 medical devices, 7,153 bioactive supplements, and related categories. Its core technology platform is the Medpharm Portal, an integrated information system for monitoring pharmaceutical production-to-consumption processes, complemented by a Reference Pricing Database covering approximately 2,500 prescription drugs (benchmarking against Kazakhstan, Russia, Turkey, and EU markets), a Digital Marking System integrated with CRPT Turon for supply chain traceability, the Farma mobile application (iOS/Android), and the farma.uzex.uz electronic trade platform.

The agency's business model is non-commercial: it is funded by the Uzbek state budget and derives no revenue from product sales or licensing fees. Its "customers" are the entities it regulates, and its go-to-market motion is event-driven — organizing international business forums, bilateral delegations, and cooperation discussions to facilitate market access for Uzbek manufacturers (notably into the ~US$1 billion Afghan market, China, and South Korea) and to attract foreign direct investment. Recent strategic activity centers on the Tashkent Smart Bio-Cluster (backed by $2.5 billion in Korean KIND investment funds), the Tashkent Pharma Park (Bio Pharma City) spanning 21,688 hectares, the Pharmaceutical Technical University, and expanding bilateral pharmaceutical cooperation with Afghanistan (AFDA), China (Sinopharm CNBG, Beijing SaituoSen), and South Korea (KIND, YUIL Trading). The agency does not compete commercially; its competitive position is defined entirely by its statutory monopoly on pharmaceutical sector regulation, reinforced by Presidential Decree PF-137 (August 2025) mandating GMP certification for all manufacturers.

Name

Agency for the Development of the Pharmaceutical Industry

Legal name

Tibbiyot va farmatsevtika tarmog'ini rivojlantirish agentligi

Website

https://uzpharmagency.uz

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

501–1,000 employees

Short description

The Agency for the Development of the Pharmaceutical Industry is Uzbekistan's government regulatory body overseeing pharmaceutical registration, GMP certification, and reference pricing for 443 manufacturers, 464 distributors, and 13,725 pharmacies via the Medpharm Portal and Digital Marking System.

Ownership category

akta.pro rank

Product category

Pharmaceutical Regulation

NAICS

Regulation, Licensing, and Inspection of Miscellaneous Commercial Sectors (92615)

akta.pro industry

PRIMARYHLAJADAG

Manufacturing Quality, GMP Inspections & Compliance

Healthcare & Life Sciences/Public Health, Government & Regulators/Medicines & Healthcare Product Regulators (Drugs/Biologics/Devices)

SECONDARYHLAJADAA

Drug Regulators (Human Pharmaceuticals)

Healthcare & Life Sciences/Public Health, Government & Regulators/Medicines & Healthcare Product Regulators (Drugs/Biologics/Devices)

SECONDARYHLAJACAI

Controlled Substances & Pharmacy Regulation Authorities

Healthcare & Life Sciences/Public Health, Government & Regulators/Health Policy, Regulation & Compliance Authorities

Keywords

• Pharmaceutical regulation
• GMP certification
• Drug registration
• Pharmaceutical pricing
• Medical device oversight

Headquarters

HQ city

Tashkent

HQ country

Uzbekistan

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure

Revenue model

1. Government Funding: The agency operates as a government body funded by the state budget, providing regulatory oversight and support services to the pharmaceutical sector rather than generating commercial revenue.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

The Agency for the Development of the Pharmaceutical Industry (Tibbiyot va farmatsevtika tarmog'ini rivojlantirish agentligi) is a government regulatory body that oversees registration, licensing, and regulation of medicines and medical devices in Uzbekistan. It operates the Medpharm Portal, administers GMP certification, maintains a reference pricing system for approximately 2,500 prescription drugs, and facilitates market access for domestic and foreign pharmaceutical manufacturers through bilateral trade agreements and digital marking systems.

Product overview

The Agency operates the Medpharm Portal as its primary unified platform for pharmaceutical regulation, offering a comprehensive ecosystem that includes a product database with 44,413 registered drug products, medical devices, bioactive supplements, medicinal plants, cosmetics, and pharmaceutical substances, along with 443 manufacturers, 464 distributors, and 13,725 pharmacies. The ecosystem also features a reference pricing system, the Tashkent Pharma Park (Bio Pharma City) pharmaceutical cluster, a Pharmaceutical Technical University, the Farma mobile app, and the farma.uzex.uz electronic trade platform.

Differentiator

Problem solved

Functional benefit

Brands

• farma.uzex.uz: Electronic platform for pharmaceutical trade and distribution

Products and services

• Medpharm Portal
• Farma Mobile App A mobile application available on iOS and Android platforms providing access to pharmaceutical services, regulatory information, and reference drug pricing data for users in Uzbekistan.
• Reference Pricing System (Referent narxlar) A reference pricing database for medicines, including wholesale and retail prices, price monitoring dashboards, and reference price lists for approximately 2,500 prescription drugs compared against international markets including Kazakhstan, Russia, Turkey, Bulgaria, Hungary, Moldova, Egypt, Romania, Ukraine, and Poland.
• Tashkent Pharma Park (Bio Pharma City) An innovative scientific-production pharmaceutical cluster spanning 21,688 hectares, including medicinal plant cultivation area producing 21,371 tons of output annually, with tax and customs incentives for manufacturers.
• Pharmaceutical Technical University A technical university offering pharmaceutical education and training programs to build domestic pharmaceutical workforce capacity in Uzbekistan.
• Pharmaceutical Product Database A comprehensive database containing 44,413 registered drug products, 11,458 medical devices, 7,153 bioactive supplements, 384 medicinal plants, 586 cosmetics, 1,023 pharmaceutical substances, and registrations of 443 manufacturers, 464 distributors, and 13,725 pharmacies.
• farma.uzex.uz Electronic Platform An electronic platform for pharmaceutical trade and commerce operations supporting the distribution and sale of registered pharmaceutical products.

Quantifiable outcome

• GMP inspection fee waived for Uzbek manufacturers entering Afghan market
• +1 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• China National Biotech Group Company Limited (Sinopharm CNBG)coreStrategic or Co-development Partner · 29 June 2026Meeting with China's leading biopharmaceutical companies including Sinopharm CNBG and Yangi Osiyo Xalqaro Biofarmasevtika to discuss biotechnology cooperation, technology transfer, and market access in Uzbekistan.
• Afghanistan Food and Drug Authority (AFDA)coreStrategic or Co-development Partner · 23 June 2026Bilateral pharmaceutical cooperation between Uzbekistan and Afghanistan. AFDA presented the Afghan pharmaceutical market (~$1 billion) and waived GMP inspection fees for Uzbek manufacturers, facilitating market entry.
• Beijing SaituoSen BiotechnologycoreStrategic or Co-development Partner · 22 June 2026Cooperation discussions focused on joint R&D projects, transfer of Chinese biotechnologies to Uzbekistan production facilities, and programs for scientific experience exchange in oncology treatments.
• Korea-Uzbekistan Cooperation ForumcoreStrategic or Co-development Partner · 21 June 2026Business forum co-organized with Herald Media Group and Uzbekistan's Ministry of Investment, Industry and Trade. Precursor to first Korea-Central Asia Summit in Seoul in September 2026. Featured cooperation agreement for Tashkent Smart Bio Cluster project.
• Uzbekistan Ministry of Investments, Industry and TradecoreStrategic or Co-development Partner · 17 June 2026Trilateral memorandum signed between Ministry, Agency for Pharmaceutical Industry Development, and KIND to establish joint investment platforms for pharmaceutical sector development.
• Afghanistan Food and Drug AdministrationcoreStrategic or Co-development Partner · 6 April 2026Working meeting in Kabul to expand pharmaceutical cooperation. Discussed simplification of lengthy drug registration procedures in Afghanistan, establishment of demonstration showrooms, involvement in Afghan government procurement, and cooperation with major Afghan distributors.
• Triumph Junheng (Chinese Company)minorStrategic or Co-development Partner · 24 March 2026Discussions on investment prospects in Uzbekistan's pharmaceutical sector, focusing on projects at 'Tashkent Pharma Park' (Bio Pharma City) including manufacturing facilities and research infrastructure with tax and customs incentives.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Regional players

• Roszdravnadzor (Federal Service for Surveillance in Healthcare): Russia's federal healthcare and pharmaceutical regulator; relevant as a larger post-Soviet regulatory peer whose pricing, GMP, and registration approaches directly affect Uzbekistan's reference pricing comparisons.
• Turkish Medicines and Medical Devices Agency (TITCK): Turkey's national pharma and medical device regulator; comparable in scope to the agency and one of the reference markets for Uzbekistan's drug price benchmarking.

Others

• WHO Prequalification Programme: WHO programme assessing medicines, vaccines, and diagnostics quality for UN procurement; relevant as an international standards-setter whose benchmarks inform the agency's GMP and registration approach.
• Ministry of Health of the Republic of Uzbekistan: Uzbekistan's parent ministry for healthcare and the supervisory body of the Agency for the Development of the Pharmaceutical Industry; relevant as a domestic institutional counterpart and policy owner.
• Ministry of Investments, Industry and Trade of Uzbekistan: Co-signatory with the agency and Korea's KIND on the $2.5B trilateral memorandum for pharmaceutical sector investment; a key domestic counterpart for industrial policy execution.

Broad incumbents

• Ministry of Food and Drug Safety (MFDS, South Korea): Korea's national pharmaceutical regulator and counterpart in the bilateral cooperation framework tied to KIND's $2.5B investment pool and the Tashkent Smart Bio-Cluster.
• Central Drugs Standard Control Organisation (CDSCO, India): India's national drug regulator, comparable in scope and relevant as a major source of generic pharmaceuticals supplying Uzbekistan and the broader Central Asian market.
• U.S. Food and Drug Administration (FDA): Global benchmark for pharmaceutical regulation covering drug registration, GMP inspections, and pricing oversight; relevant as a structural peer and reference standard for the agency's GMP certification framework.
• National Medical Products Administration (NMPA, China): China's national pharmaceutical regulator and the apex body overseeing entities such as Sinopharm CNBG and Beijing SaituoSen that engage with the Uzbek agency on technology transfer and biotech cooperation.

Direct peers

• Afghanistan Food and Drug Authority (AFDA): Afghanistan's national pharmaceutical regulator and the agency's most directly comparable peer; AFDA is a signatory of the bilateral cooperation arrangement covering GMP, drug registration simplification, and Uzbek manufacturer access to the ~$1B Afghan market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UC1rJ69k0aD_EEs9PbWLyNYQ
• Facebookfacebook.com/uzpharmagenc
• Instagraminstagram.com/uzpharm_agency
• Xx.com/Uzpharm_agency
• LinkedInlinkedin.com/company/pharmaceutical-industry-development-agency-ministry-of-health-republic-of-uzbekistan

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Agency for the Development of the Pharmaceutical Industry